| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Large-scale association analysis identifies new risk loci for coronary artery disease.
|
Nat Genet
|
2012
|
7.59
|
|
2
|
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
|
Circulation
|
2003
|
4.31
|
|
3
|
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
|
Eur Heart J
|
2006
|
3.10
|
|
4
|
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
|
Circulation
|
2013
|
3.02
|
|
5
|
Common variants associated with plasma triglycerides and risk for coronary artery disease.
|
Nat Genet
|
2013
|
2.92
|
|
6
|
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
2.90
|
|
7
|
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
|
Circulation
|
2012
|
2.74
|
|
8
|
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
|
J Am Coll Cardiol
|
2012
|
2.41
|
|
9
|
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease.
|
J Am Coll Cardiol
|
2003
|
2.36
|
|
10
|
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.
|
Thromb Haemost
|
2014
|
2.29
|
|
11
|
Genetically determined height and coronary artery disease.
|
N Engl J Med
|
2015
|
2.24
|
|
12
|
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
|
Eur Heart J
|
2011
|
2.21
|
|
13
|
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
|
J Am Coll Cardiol
|
2008
|
1.83
|
|
14
|
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2013
|
1.77
|
|
15
|
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.
|
J Am Coll Cardiol
|
2003
|
1.75
|
|
16
|
Anticoagulants in heart disease: current status and perspectives.
|
Eur Heart J
|
2007
|
1.73
|
|
17
|
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
|
Eur Heart J
|
2007
|
1.61
|
|
18
|
Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface.
|
J Thorac Cardiovasc Surg
|
2002
|
1.44
|
|
19
|
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
|
Eur Heart J
|
2007
|
1.43
|
|
20
|
Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome.
|
Circulation
|
2007
|
1.41
|
|
21
|
Sensitive plasma protein analysis by microparticle-based proximity ligation assays.
|
Mol Cell Proteomics
|
2009
|
1.37
|
|
22
|
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
|
Thromb Haemost
|
2013
|
1.36
|
|
23
|
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
|
Eur Heart J
|
2009
|
1.27
|
|
24
|
Antiplatelet agents for the treatment and prevention of atherothrombosis.
|
Eur Heart J
|
2011
|
1.23
|
|
25
|
ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing.
|
PLoS One
|
2011
|
1.21
|
|
26
|
Genetic determinants of dabigatran plasma levels and their relation to bleeding.
|
Circulation
|
2013
|
1.10
|
|
27
|
Biomarkers in atrial fibrillation: a clinical review.
|
Eur Heart J
|
2013
|
1.07
|
|
28
|
Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
|
Am J Cardiol
|
2006
|
1.02
|
|
29
|
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy.
|
J Am Coll Cardiol
|
2006
|
1.02
|
|
30
|
Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
|
Eur Heart J
|
2007
|
1.01
|
|
31
|
High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men.
|
Am Heart J
|
2013
|
1.00
|
|
32
|
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
|
Thromb Haemost
|
2013
|
0.99
|
|
33
|
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
|
Circulation
|
2013
|
0.99
|
|
34
|
GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men.
|
PLoS One
|
2013
|
0.98
|
|
35
|
Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome.
|
Circ Cardiovasc Genet
|
2009
|
0.95
|
|
36
|
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
|
Thromb Haemost
|
2008
|
0.95
|
|
37
|
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
|
Arterioscler Thromb Vasc Biol
|
2006
|
0.92
|
|
38
|
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
|
Eur Heart J
|
2003
|
0.92
|
|
39
|
Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes.
|
Arterioscler Thromb Vasc Biol
|
2005
|
0.92
|
|
40
|
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
|
Platelets
|
2013
|
0.91
|
|
41
|
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
|
Clin Chem
|
2011
|
0.90
|
|
42
|
A detailed cardiovascular characterization of obesity without the metabolic syndrome.
|
Arterioscler Thromb Vasc Biol
|
2011
|
0.88
|
|
43
|
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
|
Am Heart J
|
2009
|
0.87
|
|
44
|
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy).
|
Am J Cardiol
|
2005
|
0.87
|
|
45
|
Evaluation of microparticles in whole blood by multicolour flow cytometry assay.
|
Scand J Clin Lab Invest
|
2013
|
0.86
|
|
46
|
Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome.
|
Thromb Res
|
2006
|
0.86
|
|
47
|
A quantitative real-time PCR method for tissue factor mRNA.
|
Thromb Res
|
2003
|
0.86
|
|
48
|
Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein.
|
Mol Cancer Res
|
2009
|
0.85
|
|
49
|
Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa.
|
Thromb Res
|
2007
|
0.85
|
|
50
|
Niemann-Pick C1 modulates hepatic triglyceride metabolism and its genetic variation contributes to serum triglyceride levels.
|
Arterioscler Thromb Vasc Biol
|
2010
|
0.84
|
|
51
|
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.
|
Am Heart J
|
2005
|
0.83
|
|
52
|
Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects.
|
Scand J Clin Lab Invest
|
2011
|
0.83
|
|
53
|
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
|
Thromb Haemost
|
2016
|
0.83
|
|
54
|
NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO).
|
Circ Cardiovasc Genet
|
2015
|
0.82
|
|
55
|
Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease.
|
Int J Cardiol
|
2005
|
0.82
|
|
56
|
C-reactive protein and e-selectin levels are related to vasodilation in resistance, but not conductance arteries in the elderly: the prospective investigation of the Vasculature in Uppsala Seniors (PIVUS) study.
|
Atherosclerosis
|
2007
|
0.81
|
|
57
|
CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell function during the first year after diagnosis of type 1 diabetes.
|
Diabetes Metab Res Rev
|
2004
|
0.81
|
|
58
|
Enhanced platelet activation mediates the accelerated angiogenic switch in mice lacking histidine-rich glycoprotein.
|
PLoS One
|
2011
|
0.81
|
|
59
|
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study.
|
Clin Chem
|
2013
|
0.81
|
|
60
|
Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery.
|
Thromb Res
|
2009
|
0.80
|
|
61
|
The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment.
|
Thromb Res
|
2006
|
0.80
|
|
62
|
Variants of the interferon regulatory factor 5 gene regulate expression of IRF5 mRNA in atherosclerotic tissue but are not associated with myocardial infarction.
|
Arterioscler Thromb Vasc Biol
|
2008
|
0.79
|
|
63
|
Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups "Atherosclerosis & Vascular Biology" and "Thrombosis".
|
Thromb Haemost
|
2016
|
0.79
|
|
64
|
Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction.
|
Thromb Res
|
2002
|
0.78
|
|
65
|
PML/RARalpha plays a role for basal activity and retinoid-induced repression of the tissue factor promoter in acute promyelocytic leukemia cells.
|
Thromb Haemost
|
2003
|
0.78
|
|
66
|
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
|
Am Heart J
|
2008
|
0.77
|
|
67
|
Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells.
|
Thromb Haemost
|
2008
|
0.77
|
|
68
|
HRG regulates tumor progression, epithelial to mesenchymal transition and metastasis via platelet-induced signaling in the pre-tumorigenic microenvironment.
|
Angiogenesis
|
2013
|
0.77
|
|
69
|
Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin.
|
Thromb Res
|
2002
|
0.76
|
|
70
|
Identification of novel downstream molecules of tissue factor activation by comparative proteomic analysis.
|
J Proteome Res
|
2013
|
0.76
|
|
71
|
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
|
Am Heart J
|
2004
|
0.76
|
|
72
|
IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets.
|
Thromb Haemost
|
2017
|
0.76
|
|
73
|
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy".
|
Circulation
|
2013
|
0.75
|
|
74
|
The intersubject variability of tissue factor mRNA production in human monocytes--relation with the toll-like receptor 4.
|
Thromb Res
|
2006
|
0.75
|
|
75
|
[Prophylaxis of postoperative thromboembolism. New alternatives to low-molecular-weight heparin].
|
Lakartidningen
|
2002
|
0.75
|
|
76
|
The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression.
|
Thromb Res
|
2010
|
0.75
|
|
77
|
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
|
Am Heart J
|
2012
|
0.75
|
|
78
|
Expression of fibrinolytic and coagulation factors in cocultured human endothelial and smooth muscle cells.
|
Tissue Eng
|
2004
|
0.75
|
|
79
|
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
|
Am Heart J
|
2011
|
0.75
|
|
80
|
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
|
Thromb Haemost
|
2004
|
0.75
|
|
81
|
Microparticles during long-term follow-up after acute myocardial infarction. Association to atherosclerotic burden and risk of cardiovascular events.
|
Thromb Haemost
|
2017
|
0.75
|
|
82
|
[Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice].
|
Lakartidningen
|
2004
|
0.75
|